查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842299

美国医药CDMO市场：市场规模、份额和趋势分析（按类型、产品、服务、工作流程、治疗领域和最终用途划分），细分市场预测（2025-2033年）

U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Services, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国製药CDMO市场概览

据估计，2024 年美国药品 CDMO 市值为 365 亿美元，预计到 2033 年将达到 653 亿美元，2025 年至 2033 年的复合年增长率为 6.74%。

美国製药 CDMO（合约开发和生产组织）产业蓬勃发展，这得益于生技药品、生物相似药和先进疗法的增长，药物开发外包需求的增加，临床试验活动的活性化以及研发管线的扩展。

美国市场在生技药品、生物相似药以及先进的细胞和基因疗法方面正经历显着增长，从而推动了对专业CDMO服务的需求。这些疗法的研发和生产需要先进的能力，例如一次性生物製程系统、病毒载体生产以及个人化医疗方面的专业知识，而许多製药公司并不具备这些能力。

CDMO（合约研发生产机构）提供基础设施、监管知识和创新平台，以加速产品开发并符合FDA标准。随着越来越多的生技药品和生物相似药在美国核准，CDMO已成为扩大生产规模、确保供应链韧性以及加速复杂、高价值治疗药物上市速度的关键合作伙伴。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：美国医药CDMO市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
  • 研发费用分析
  • 产业生态系分析
    • 需求分析
    • 供应链分析
  • 技术格局
  • 临床实验数量分析（2024 年）
  • 定价分析
  • 分析关税和贸易协定的影响
  • 价值链分析
    • 供应趋势
    • 需求趋势
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析与SWOT分析

第四章：美国医药CDMO市场：按类型分類的估算与趋势分析

  • 美国医药CDMO市场：按类型分類的概览
  • 美国医药CDMO市场：按类型分類的变化分析
  • 按类型（2021-2033 年）
  • 低分子
    • 品牌
    • 非专利的
  • 聚合物
    • 生物製药
    • 生物相似药

第五章：美国医药CDMO市场：按产品分類的估算与趋势分析

  • 美国製药CDMO市场：产品概览
  • 美国医药CDMO市场：按产品分類的变化分析
  • 按类型（2021-2033 年）
  • API（原料药）
    • 传统 API
    • 高活性原料药（HP-API）
    • 生技药品
    • 其他的
  • 製药
    • 口服固态剂型
    • 半固态
    • 液体剂型
    • 其他的

第六章：美国医药CDMO市场：按服务类型分類的估算与趋势分析

  • 美国医药CDMO市场：按服务分类的概览
  • 美国医药CDMO市场：按服务类型分類的变化分析
  • 依服务年资（2021-2033）
  • 合约开发
    • 预配方和配方开发服务
    • 製程开发与最佳化
    • 分析测试和方法检验
    • 规模化和技术转移
  • 契约製造
    • API生产
    • 成品药生产
  • 包装和标籤
  • 监管事务
  • 其他的

第七章：美国製药CDMO市场：依工作流程分類的估算与趋势分析

  • 美国製药CDMO市场：工作流程仪錶板
  • 美国製药CDMO市场：按工作流程分類的差异分析
  • 按工作流程（2021-2033）
  • 临床
  • 上市

第八章：美国医药CDMO市场：依治疗领域分類的估算与趋势分析

  • 美国製药CDMO市场：治疗领域概览
  • 美国製药CDMO市场：按治疗领域分類的变化分析
  • 依治疗领域划分（2021-2033 年）
  • 瘤
  • 感染疾病
  • 神经系统疾病
  • 心血管疾病
  • 代谢紊乱
  • 自体免疫疾病
  • 呼吸系统疾病
  • 眼科
  • 胃肠道疾病
  • 整形外科疾病
  • 牙科疾病
  • 其他的

第九章：美国医药CDMO市场：依最终用途分類的估算与趋势分析

  • 美国医药CDMO市场：按最终用途分類的概览
  • 美国医药CDMO市场：依最终用途分類的变化分析
  • 依最终用途划分（2021-2033 年）
  • 小型製药公司
  • 中型製药公司
  • 大型製药企业

第十章 竞争格局

  • 主要参与企业的分类
    • 市场领导
    • 新兴企业
  • 市占率/估值分析（热力图分析），2024 年
  • 公司简介
    • Thermo Fisher Scientific, Inc
    • Lonza
    • Recipharm AB
    • Catalent, Inc
    • WuXi AppTec, Inc
    • Samsung Biologics
    • Piramal Pharma Solutions
    • Siegfried Holding AG
    • Corden Pharma International
    • Cambrex Corporation
    • Vetter Pharma
    • Delpharm
    • Jubilant Pharmova/HollisterStier
    • Eurofins CDMO
    • Almac Pharma Services
Product Code: GVR-4-68040-754-9

U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Summary

The U.S. pharmaceutical contract development and manufacturing organization market size was estimated at USD 36.5 billion in 2024 and is projected to reach USD 65.3 billion by 2033, growing at a CAGR of 6.74% from 2025 to 2033. The U.S. pharmaceutical contract development & manufacturing organization (CDMO) is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion.

The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house.

CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmaceutical CDMO market report based on type, product, service, workflow, therapeutic area, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
    • Branded
    • Generic
  • Large Molecule
    • Biologics
    • Biosimilar
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • API
    • Traditional Active Pharmaceutical Ingredient (Traditional API)
    • Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • Biologics
    • Others
  • Drug Product
    • Oral solid dose
    • Semi-solid dose
    • Liquid dose
    • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
    • Pre-formulation & Formulation Development Services
    • Process Development & Optimization
    • Analytical Testing & Method Validation
    • Scale-up & Tech Transfer
  • Contract Manufacturing
    • API Manufacturing
    • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Others
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Pharmaceutical Companies
  • Medium Pharmaceutical Companies
  • Large Pharmaceutical Companies

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Services
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
  • 3.3. R&D Spending Analysis
  • 3.4. Industry Ecosystem Analysis
    • 3.4.1. Demand Analysis
    • 3.4.2. Supply Chain Analysis
  • 3.5. Technology Landscape
  • 3.6. Clinical Trial Volume Analysis, 2024
  • 3.7. Pricing Analysis
  • 3.8. Tariff and Trade Agreement Impact Analysis
  • 3.9. Value Chain Analysis
    • 3.9.1. Supply Trends
    • 3.9.2. Demand Trends
  • 3.10. Market Analysis Tools
    • 3.10.1. Porter's Five Forces Analysis
    • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
  • 4.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
  • 4.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Branded
      • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Generic
      • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilar
      • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
  • 5.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
  • 5.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
  • 5.4. API
    • 5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Biologics
      • 5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Drug Product
    • 5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Oral Solid Dose
      • 5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Semi-Solid Dose
      • 5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Liquid Dose
      • 5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
  • 6.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
  • 6.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Pre-formulation & Formulation Development Services
      • 6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Process Development & Optimization
      • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Analytical Testing & Method Validation
      • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Scale-up & Tech Transfer
      • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. API Manufacturing
      • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Finished Drug Products Manufacturing
      • 6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Packaging and Labelling
    • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Regulatory Affairs
    • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
  • 7.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
  • 7.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 7.4. Clinical
    • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Commercial
    • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
  • 8.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
  • 8.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Neurological Disorders
    • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Cardiovascular Diseases
    • 8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Metabolic Disorders
    • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Autoimmune Diseases
    • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Respiratory Diseases
    • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Ophthalmology
    • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Gastrointestinal Disorders
    • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Orthopedic Diseases
    • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.14. Dental Diseases
    • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.15. Others
    • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
  • 9.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
  • 9.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 9.4. Small Pharmaceutical Companies
    • 9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medium Pharmaceutical Companies
    • 9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Large Pharmaceutical Companies
    • 9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Key Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Thermo Fisher Scientific, Inc
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Lonza
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Recipharm AB
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Catalent, Inc
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. WuXi AppTec, Inc
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Samsung Biologics
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Piramal Pharma Solutions
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Siegfried Holding AG
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Corden Pharma International
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Cambrex Corporation
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Vetter Pharma
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Delpharm
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Jubilant Pharmova / HollisterStier
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Eurofins CDMO
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Almac Pharma Services
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 5 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type outlook and key takeaways
  • Fig. 20 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type movement analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product outlook and key takeaways
  • Fig. 28 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product movement analysis
  • Fig. 29 Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service outlook and key takeaways
  • Fig. 41 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service movement analysis
  • Fig. 42 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Pre-formulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow outlook and key takeaways
  • Fig. 54 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow movement analysis
  • Fig. 55 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area outlook and key takeaways
  • Fig. 58 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area movement analysis
  • Fig. 59 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 72 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use movement analysis
  • Fig. 73 Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key company categorization
  • Fig. 77 Service heat map analysis
  • Fig. 78 Strategic framework